600.06 Clinical and Hemodynamic Predictors of Subclinical Leaflet Thrombosis in Low-Risk Patients undergoing Transcatheter Aortic Valve Replacement (TAVR)

The Low Risk TAVR trial was the first FDA-approved trial of transcatheter aortic valve replacement (TAVR) in low-surgical-risk patients in the United States. 14% developed hypoattenuated leaflet thrombosis (HALT) on 30-day computerized tomography (CT) scan. HALT likely represents subclinical leaflet